REGN

$961.263.60%33.37

Pre-mercato: 963.21+1.95 +0.20%

Regeneron Pharmaceuticals Inc (REGN)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$927.89

Aprire:

$927.22

Volume 24 ore:

1,661,161

Volume relativo:

1.73

Capitalizzazione di mercato:

$99.44B

Reddito:

$14.92B

Utile/perdita netta:

$4.42B

Rapporto P/E:

23.42

EPS:

$41.04

Flusso di cassa netto:

$3.79B

1W Prestazione:

+17.79%

1M Prestazione:

+30.75%

6M Prestazione:

+37.04%

1Y Prestazione:

+49.67%

Intervallo 1D:

$0.00$0.00

Intervallo di 1 settimana:

$802.20$974.00

Portata 52W:

$591.52$974.00

Profilo aziendale di Regeneron Pharmaceuticals Inc (REGN)

Nome

Regeneron Pharmaceuticals Inc

Settore

Healthcare

Industria

Biotechnology

Telefono

(914) 847-7000

Indirizzo

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, USA

Dipendente

15,410

@regeneron

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di REGN su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Regeneron Pharmaceuticals Inc Azioni (REGN) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-10-01	Aggiornamento	Argus	Hold → Buy
2026-05-18	Downgrade	Citigroup	Buy → Neutral
2026-05-18	Downgrade	Leerink Partners	Outperform → Market Perform
2026-03-31	Resumed	Piper Sandler	Overweight
2026-03-06	Iniziato	Barclays	Overweight
2026-01-07	Aggiornamento	BofA Securities	Underperform → Buy
2025-12-03	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	Iniziato	HSBC Securities	Buy
2025-11-24	Resumed	Truist	Buy
2025-11-13	Iniziato	Scotiabank	Sector Perform
2025-08-14	Iniziato	Rothschild & Co Redburn	Buy
2025-06-30	Downgrade	Argus	Buy → Hold
2025-05-30	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-05-14	Aggiornamento	Citigroup	Neutral → Buy
2025-04-22	Resumed	Cantor Fitzgerald	Overweight
2025-02-05	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-01-16	Downgrade	UBS	Buy → Neutral
2024-12-10	Resumed	BofA Securities	Underperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-11-14	Iniziato	Citigroup	Neutral
2024-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
2024-03-12	Iniziato	Bernstein	Outperform
2024-01-12	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-11-03	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-08-21	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-08-21	Reiterato	Oppenheimer	Perform
2023-06-28	Downgrade	Canaccord Genuity	Buy → Hold
2023-03-27	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-24	Aggiornamento	Jefferies	Hold → Buy
2023-03-23	Aggiornamento	Raymond James	Underperform → Mkt Perform
2023-01-30	Aggiornamento	Cowen	Market Perform → Outperform
2023-01-20	Aggiornamento	JP Morgan	Neutral → Overweight
2022-10-26	Downgrade	Raymond James	Mkt Perform → Underperform
2022-10-17	Downgrade	Evercore ISI	Outperform → In-line
2022-09-09	Aggiornamento	Jefferies	Underperform → Hold
2022-09-09	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-06	Iniziato	Jefferies	Underperform
2022-05-23	Iniziato	SVB Leerink	Outperform
2022-01-05	Downgrade	BofA Securities	Neutral → Underperform
2022-01-03	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-12-15	Downgrade	Bernstein	Outperform → Mkt Perform
2021-12-09	Resumed	Wells Fargo	Overweight
2021-12-07	Resumed	Cowen	Market Perform
2021-12-06	Iniziato	Goldman	Buy
2021-11-19	Resumed	BMO Capital Markets	Outperform
2021-11-05	Downgrade	The Benchmark Company	Buy → Hold
2021-06-29	Iniziato	H.C. Wainwright	Buy
2021-01-25	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Aggiornamento	The Benchmark Company	Hold → Buy
2021-01-08	Aggiornamento	Citigroup	Neutral → Buy
2020-10-05	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Downgrade	The Benchmark Company	Buy → Hold
2020-07-09	Aggiornamento	SunTrust	Hold → Buy
2020-05-26	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-04-28	Downgrade	Citigroup	Buy → Neutral
2020-04-17	Aggiornamento	The Benchmark Company	Hold → Buy
2020-04-08	Iniziato	The Benchmark Company	Hold
2020-03-31	Iniziato	Wolfe Research	Peer Perform
2020-02-27	Iniziato	Barclays	Overweight
2020-02-26	Aggiornamento	Canaccord Genuity	Hold → Buy
2020-02-26	Downgrade	Robert W. Baird	Outperform → Neutral
2020-02-25	Aggiornamento	Jefferies	Hold → Buy
2020-02-11	Aggiornamento	Argus	Hold → Buy
2019-12-24	Iniziato	Raymond James	Mkt Perform
2019-12-16	Downgrade	Evercore ISI	Outperform → In-line
2019-12-13	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-11-12	Iniziato	SunTrust	Hold
2019-11-07	Aggiornamento	Citigroup	Neutral → Buy
2019-10-17	Resumed	BofA/Merrill	Neutral
2019-09-23	Aggiornamento	Guggenheim	Neutral → Buy

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	14,342.90	14,202.00	13,117.20	12,172.90	16,071.70
Research and development USD (M)	5,850.20	5,132.00	4,439.00	3,592.50	2,908.10
Operating expenses USD (M)	10,765.00	10,211.30	9,070.10	7,434.00	7,124.90
Operating income USD (M)	3,577.90	3,990.70	4,047.10	4,738.90	8,946.80
Income before tax USD (M)	5,230.70	4,779.90	4,199.30	4,858.80	9,325.80
Income tax expense USD (M)	725.80	367.30	245.70	520.40	1,250.50
Net income USD (M)	4,504.90	4,412.60	3,953.60	4,338.40	8,075.30
Basic EPS USD/shares	43.07	40.90	37.05	40.51	76.40
Diluted EPS USD/shares	41.48	38.34	34.77	38.22	71.97
Basic weighted shares shares (M)	104.60	107.90	106.70	107.10	105.70
Diluted weighted shares shares (M)	108.60	115.10	113.70	113.50	112.20
Selling, general and administrative USD (M)	2,700.00	2,954.40	2,631.30	2,115.90	1,824.90

Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading

Joseph LaRosaNov 02 '26
Officer
Transazione
Proposed Sale
Costo
$965.49
#Azioni
4,466
Valore ($)
4,311,875
#Azioni Totale
0
Christine PoonNov 02 '26
Director
Transazione
Proposed Sale
Costo
$961.26
#Azioni
7,830
Valore ($)
7,526,666
#Azioni Totale
0
GEORGE L. SINGNov 02 '26
Director
Transazione
Proposed Sale
Costo
$964.38
#Azioni
21,129
Valore ($)
20,376,360
#Azioni Totale
0
Guarini KathrynOct 30 '26
Director
Transazione
Proposed Sale
Costo
$900.00
#Azioni
400
Valore ($)
360,000
#Azioni Totale
0
MICHAEL S BROWNOct 30 '26
Director
Transazione
Proposed Sale
Costo
$818.77
#Azioni
1,929
Valore ($)
1,579,407
#Azioni Totale
0
McCourt MarionOct 30 '26
Officer
Transazione
Proposed Sale
Costo
$869.43
#Azioni
1,132
Valore ($)
984,195
#Azioni Totale
0
MURPHY ANDREW JOct 14 '26
Officer
Transazione
Proposed Sale
Costo
$772.70
#Azioni
4,147
Valore ($)
3,204,380
#Azioni Totale
0
MURPHY ANDREW JOct 14 '26
Co-Chief Scientific Officer
Transazione
Sale
Costo
$772.70
#Azioni
4,147
Valore ($)
3,204,376
#Azioni Totale
47,833
MURPHY ANDREW JOct 13 '26
Co-Chief Scientific Officer
Transazione
Option Exercise
Costo
$381.92
#Azioni
17,000
Valore ($)
6,492,640
#Azioni Totale
64,833
McCourt MarionSep 03 '26
EVP Commercial
Transazione
Sale
Costo
$857.39
#Azioni
1,131
Valore ($)
969,708
#Azioni Totale
12,003

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Joseph LaRosa	Officer	Nov 02 '26	Proposed Sale	$965.49	4,466	4,311,875	0
Christine Poon	Director	Nov 02 '26	Proposed Sale	$961.26	7,830	7,526,666	0
GEORGE L. SING	Director	Nov 02 '26	Proposed Sale	$964.38	21,129	20,376,360	0
Guarini Kathryn	Director	Oct 30 '26	Proposed Sale	$900.00	400	360,000	0
MICHAEL S BROWN	Director	Oct 30 '26	Proposed Sale	$818.77	1,929	1,579,407	0
McCourt Marion	Officer	Oct 30 '26	Proposed Sale	$869.43	1,132	984,195	0
MURPHY ANDREW J	Officer	Oct 14 '26	Proposed Sale	$772.70	4,147	3,204,380	0
MURPHY ANDREW J	Co-Chief Scientific Officer	Oct 14 '26	Sale	$772.70	4,147	3,204,376	47,833
MURPHY ANDREW J	Co-Chief Scientific Officer	Oct 13 '26	Option Exercise	$381.92	17,000	6,492,640	64,833
McCourt Marion	EVP Commercial	Sep 03 '26	Sale	$857.39	1,131	969,708	12,003

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

Nov 02, 2026

REGN Maintained by B of A Securities -- Price Target Raised to $1030 - GuruFocus

Nov 02, 2026

Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $812 From $756 - www.marketscreener.com

Nov 02, 2026

B of A Securities maintains Regeneron Pharmaceuticals at Buy, raises price target to $1030 from $908 - TradingView

Nov 02, 2026

Analyst recommendations: Adobe, Caterpillar, Fair Isaac, Regeneron Pharmaceuticals… - marketscreener.com

Nov 02, 2026

FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight - Yahoo Finance

Nov 02, 2026

BofA raises Regeneron stock price target on strong revenue beat By Investing.com - Investing.com Canada

Nov 02, 2026

Nov 01, 2026

Why Is Regeneron Stock Going Up? - Trefis

Nov 01, 2026

Oct 31, 2026

Regeneron: 3 Key Takeaways for Long-Term Investors - The Motley Fool

Oct 31, 2026

Oct 30, 2026